RecruitingNot ApplicableNCT05694793

Trial for Reliability of Urodynamics SysTem


Sponsor

Bright Uro

Enrollment

28 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms. The main question\[s\] it aims to answer are: • What is GUS's ability to safely and reliably conduct wireless, catheter-free monitoring of vesical pressure compared to the vesical pressures collected with conventional urodynamics? Participants will undergo a conventional urodynamics exam, a simultaneous urodynamics exam with GUS, ambulatory urodynamics with GUS, and extended home monitoring with GUS. Researchers will compare GUS data with that from a conventional urodynamics exam.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Female patient must be ≥ 18 years of age
  • Patient is a candidate for urodynamics per standard of care
  • Patient or patient's legally authorized representative is able to provide informed consent

Exclusion Criteria14

  • Pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months or intend to become pregnant during the study period
  • Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
  • Patient has history of recurrent UTIs (≥ 3 episodes in previous 12 months).
  • Patient has used antibiotics within the past 7 days from the baseline/screening visit.
  • Patient diagnosed with neurogenic LUTS (which may be associated with one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).
  • Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).
  • Patient with a urostomy.
  • Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall).
  • Patient who has from one or more major strictures in the urethra.
  • Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
  • Patient with a colostomy.
  • Patient with any abnormal or concerning rectal or vaginal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, active yeast infections, or vaginitis.
  • Patient has a known inability to void or is in complete retention.
  • Subjects who, at the principal investigator's determination, would not be appropriate for this study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEGlean Urodynamics System

Wireless, catheter-free urodynamics system

DEVICEGlean Urodynamics System

Wireless and catheter free urodynamics system


Locations(4)

Tri Valley Urology Medical Group

Murrieta, California, United States

University of California San Diego

San Diego, California, United States

Unio Health Partners

Torrence, California, United States

Cleveland Clinic

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05694793


Related Trials